

BRAIN Biotech AG

Creating a #BiobasedFuture

seat11a.com

Capital Markets Day 2023

Michael Schneiders, CFO

Zwingenberg, February 27, 2023

WE SUPPORT



Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.



Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of February, 27th, 2023. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means Brain Biotech AG and its affiliates, if not otherwise specified.


Why invest in BRAIN Biotech AG?

CMD 2023 key messages


- We service the megatrend of healthier and more sustainable food production
- We are creating a Top 10 global multi-niche food and pharma enzyme champion
- Akribion Genomics offers a key enabling technology for the biotransformation and potentially and innovative method to attach cancer cells for oncology treatments
- Operating in 3 clearly defined business pillars: BioProducts, BioScience and BioIncubator

Future Nutrition will be Produced Differently


cornerstones of sustainable food production



9.8 billion by 2050



More people
More protein



Industrial livestock farming
Ethical issues and footprints


Why?

- Industrial livestock farming has a significant GHG footprint
- Fishing grounds are being depleted
- May be considered unethical and contributes to the global antibiotics crisis
- Energy, water and land use is threatening biodiversity and the global climate

► **Industrialized countries will move away from meat and dairy towards alternative sources**

Future Nutrition will be Produced Differently


cornerstones of sustainable food production



9.8 billion by 2050



**More people
More protein**



Industrial livestock farming
Ethical issues and footprints



Precision fermentation
Alternative proteins



Enzymes
Processing of plant-based protein




Microorganisms
Fermented Food

► **Industrialized countries will move away from meat and dairy towards alternative sources**


From Candidates to Industrial Production Processes

all the technologies available to deliver the complete process


Discovery
Protein Engineering
Rational Selection



Microbial strains



Expression technology



Strain development



Bioprocess development

Industrial
production




Merging BRAIN's Products businesses under the Biocatalysts roof

BRAIN BioProducts Division




One BioProducts: the big goals

why are we doing this and where are we going?



Manufacturing footprint

growing international manufacturing and distribution setup



Numbers based on FY 2021/22



Scales of fermentation

a unique range of capabilities

Multiple small scale fermenters from 250ml to 3 litre

50l and 750l fermenters with full range of DSP including freeze drying and chromatography purification capability

10m³ fermenter on site with plans for 25m³ and partner scale to >50m³, DSP including drying at all scales



Mini 8s and 3l fermenters-

Enzyme development, process evolution, first scale up step



50l and 750l fermenters –

Enzyme development, process evolution
Scale up step
Diagnostic enzyme manufacture
Speciality high value manufacture




10m³ fermenters and more –


Manufacturing processes
Diagnostic enzyme manufacture
High value manufacture of food enzymes
Perfect pharma / life science scale

Growth Initiatives under way


large scale fermentation expansion project and site expansion



February '23



June '24



Akribion Genomics – Vision and mission

democratizing access to Genome Editing tools
enabling novel opportunities to edit the living for the better




We have a clear vision:

To become a **leading player** in the **genome editing landscape**...
... by **enabling others** with the **tools and technology** (“picks & shovels”)...
... to edit the living for the better



Our mission is twofold: Enable new opportunities and democratize access

- Make new **treatment approaches** in **oncology** and **other opportunities** possible by developing **novel technology** with **unique properties**
- **Democratize access** to advanced CRISPR genome editing technology **with freedom to operate**



We serve and win in a variety of markets:



Therapeutics



Industrial
Biotech



Diagnostics




Agriculture

...we call it *Gediting*

Akribion Genomics – Unique Technology Platform

two distinct proprietary CRISPR nuclease families that can go beyond the limitations of current genome editing tools


G-dase M



- (Family of) Class II Type V CRISPR enzyme(s) useful for targeted gene editing
- Wildtype sequence from unknown organisms with low sequence similarity to Cpf1 / Cas12a (<40%)
- Genome editing activity in prokaryotes, eukaryotes incl. mammalian/human cells

Positioned as an alternative to existing CRISPR tools with easier access and freedom-to-operate

G-dase E



- Novel Class II CRISPR enzyme with a RNA-dependent 'guided toxicity' Mode of Action
- Hybrid nuclease based on metagenome-derived sequences and in-silico based protein engineering
- Fosters genome editing activity in prokaryotes, eukaryotes incl. mammalian/human cells








Represents a novel therapeutics class and can improve diagnostics and industrial processes

Akribion Genomics – A Very Exciting Business Opportunity

- Unique technology platform with the potential to create a new class of treatment for cancer → Edit the living for the better!
- Huge market potential in therapeutics with highly attractive alternative use cases
- Strong partners are successively confirming the viability of our technology
- Spinning out Akribion allows for a more condensed focus on therapeutics and a venture capital style investment approach with the long term target exit as an own IPO

Efficient & Transparent Organization

aligning external reporting with business accountability

<div>BRAIN Biotech AG</div> <div>Creating a #BiobasedFuture</div> <div>Holding Costs ~€3.0m</div>		
BioProducts	BioScience	BioIncubator
Application Based Fermentation & Formulation	Bespoke Customer Solutions	Building the Future in Biotech
Enzyme & Food Ingredients Specialist	Solutions for Nutrition, Healthcare & Environment	Incubator Pipeline Projects & Participations
Food & Beverage Healthcare Production Scale-up Large Scale Fermentation Cell Factories Precise Fermentation	Discovery In-Vivo Gene/Protein Engineering Bioprocess Development Strain Development & Licensing Bioactives Small Molecules for Pharma	Breakthrough Discoveries Proprietary Genome Editing Partnered Investments Pharma Spin-Outs Licensed-Out
~ €37.5m Annual Revenues ~13 % + adj. EBITDA Margin	~ €12.1m Annual Revenues ~ 4-6% adj. EBITDA Margin Create Additional Upside via TMS + *	~ €4m - €5m Total Investments thereof ~€2m Akribion Genomics
<div><div> BIOCATALYSTS</div><div>A BRAIN Group company</div><div> BREATEC</div><div> Weiss•Bio•Tech</div><div> Biosun</div></div>	<div><div>B•R•A•I•N</div><div>Zwingenberg</div><div> AnalytiCon</div><div>discovery</div><div>A BRAIN Group company</div></div>	<div><div>B•R•A•I•N</div><div>Incubator</div><div>Partnered Breakthrough Projects</div></div> <div><div> Akribion Genomics</div><div>Genome Editing Spin-Out, 100%</div></div> <div><div> SolasCure</div><div>Pharma Spin-Out, 35.5 % stake</div></div> <div><div>PHA121</div><div>Pharma Licensed-Out, Royalties</div></div>

*TMS+ = Tech Access Fees, Royalties & Production Strain Licensing

All numbers FY '21/22



harvesting clearly defined synergies within the group, sustainability embedded



Efficient & Transparent Organization

gaining financial flexibility via strategic reorganization

<div> BRAIN Biotech AG Holding <ul style="list-style-type: none"> ❖ Active portfolio management ❖ Facilitate cross-divisional synergies ❖ Drive M&A ❖ Equity financing for strategic considerations </div>		
One BioProducts	BioScience	BioIncubator
<div> </div> <ul style="list-style-type: none"> • High organic growth • Bolt-on M&A • Solid cash flow • Good debt capacity • Dividend upstreaming to holding 	<div> </div> <ul style="list-style-type: none"> • Engine for One BioProducts & Incubator • Enabling BRAIN as integrated solutions provider • TMS+* driving future profitability 	<div> </div> <ul style="list-style-type: none"> • Further increased focus • Risk sharing with partners • IP driven / capital light • Spin-out • Growth financing & focus • Therapeutics Opportunity • Evaluate all options post Phase 2a • De-risk financially • Keep royalty upside • TMS / Milestones / Royalty • Clinical fully partner driven • Explore similar projects

*TMS+ = Tech Access Fees, Royalties & Production Strain Licensing



Thank you very much for your interest.

BRAIN Biotech AG

Darmstädter Straße 34–36
64673 Zwingenberg, Germany

+49 (0) 6251-9331-0
www.brain-biotech.com

Your contacts:

Michael Schneiders, CFO

+49 (0) 6251-9331-86
MiS@brain-biotech.com

Martina Schuster, IR

+49 (0) 6251-9331-69
MS@brain-biotech.com

 @BRAINbiotech

 BRAIN AG